Form 4: Spero Therapeutics Director Frank E. Thomas Receives 20,000 Restricted Stock Units

Spero Therapeutics, Inc. Director Frank E. Thomas was granted 20,000 Restricted Stock Units (RSUs) on June 12, 2025, which will vest in one year.

Summary

• Frank E. Thomas, a Director of Spero Therapeutics, Inc. (SPRO), acquired 20,000 shares of common stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on June 12, 2025.
• The RSUs were acquired at a price of $0.00 per unit, indicating a grant rather than a purchase.
• Each RSU represents the right to receive one share of common stock upon vesting.
• These RSUs are scheduled to vest on June 12, 2026, contingent upon Mr. Thomas's continued service to the company.
• Following this transaction, Frank E. Thomas beneficially owns a total of 75,000 shares of common stock directly.

Sentiment

Score: 7

Explanation: The sentiment is positive as it indicates a standard equity grant to a director, which aligns their interests with shareholders. This is a routine compensation event and does not suggest any negative underlying issues.

Positives

• The grant of Restricted Stock Units to a director aligns their interests with those of the shareholders, as the value of their compensation is tied to the company's stock performance.
• Equity compensation is a common practice to attract and retain experienced board members.

Future Outlook

The document does not provide a general future outlook for the company, focusing solely on an insider equity transaction.

Industry Context

This Form 4 filing details a standard equity compensation event for a director, a common practice across various industries to incentivize long-term commitment and align leadership interests with shareholder value. It does not provide broader industry trends or competitive analysis.

Related Party Transactions

• The acquisition of 20,000 Restricted Stock Units by Frank E. Thomas, a Director of Spero Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director helps align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: While not directly impacting general employees, such compensation practices can set precedents for executive and board remuneration.

Next Steps

• The 20,000 Restricted Stock Units are scheduled to vest on June 12, 2026, subject to the director's continued service.

Key Dates

Keywords

Spero Therapeutics, SPRO, Form 4, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Grant